Increased reporting of CVAEs in clinical trials and further research into the mechanisms underlying these cardiotoxic effects ought to provide important information to allow optimal anti-cancer utility of BRAF and MEK inhibitors while minimizing potential cardiovascular adverse effects. Here, BRAF is linked to cancer.